Cited 13 times in
A randomized, double-blind clinical trial to evaluate the efficacy and safety of a fixed-dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이상학 | - |
dc.date.accessioned | 2022-09-06T06:39:32Z | - |
dc.date.available | 2022-09-06T06:39:32Z | - |
dc.date.issued | 2020-02 | - |
dc.identifier.issn | 1524-6175 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/190254 | - |
dc.description.abstract | This multicenter, randomized, double-blind, parallel-group phase III clinical trial aimed to investigate the efficacy and safety of a rosuvastatin + amlodipine combination compared with that of rosuvastatin or amlodipine monotherapy in hypertensive patients with dyslipidemia. A total of 106 patients of 15 institutions in Korea were randomly assigned to 1 of 3 treatment groups: rosuvastatin 20 mg + amlodipine 10 mg, amlodipine 10 mg, or rosuvastatin 20 mg. After 8 weeks of treatment, the mean +/- SD of change in mean sitting systolic blood pressure (msSBP) was -22.82 +/- 12.99 mm Hg in the rosuvastatin + amlodipine group, the most decreased among the treatment groups. The percentage of patients whose msSBP decreased >= 20 mm Hg or msDBP decreased >= 10 mm Hg was also highest in this group (74.29%). The mean +/- SD percentage change in low-density lipoprotein cholesterol (LDL-C) level from baseline after 8 weeks was -52.53% +/- 11.21% in the rosuvastatin + amlodipine group, the most decreased among the treatment groups. More patients in the rosuvastatin + amlodipine group achieved their target LDL-C goal at 8 weeks, compared with the other treatment groups (97.14%). No serious adverse events or adverse drug reactions were observed in all groups. In hypertensive patients with dyslipidemia, combination treatment with rosuvastatin 20 mg + amlodipine 10 mg effectively reduced blood pressure and LDL-C levels while maintaining safety. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Wiley Periodicals Inc. | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL HYPERTENSION | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Amlodipine / therapeutic use* | - |
dc.subject.MESH | Antihypertensive Agents / therapeutic use* | - |
dc.subject.MESH | Blood Pressure / drug effects | - |
dc.subject.MESH | Double-Blind Method | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Dyslipidemias* / drug therapy | - |
dc.subject.MESH | Dyslipidemias* / epidemiology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hypertension* / drug therapy | - |
dc.subject.MESH | Republic of Korea / epidemiology | - |
dc.subject.MESH | Rosuvastatin Calcium / therapeutic use* | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | A randomized, double-blind clinical trial to evaluate the efficacy and safety of a fixed-dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Woohyeun Kim | - |
dc.contributor.googleauthor | Kiyuk Chang | - |
dc.contributor.googleauthor | Eun Joo Cho | - |
dc.contributor.googleauthor | Jeong-Cheon Ahn | - |
dc.contributor.googleauthor | Cheol Woong Yu | - |
dc.contributor.googleauthor | Kyoung-Im Cho | - |
dc.contributor.googleauthor | Yong-Jin Kim | - |
dc.contributor.googleauthor | Duk-Hyun Kang | - |
dc.contributor.googleauthor | Seok-Yeon Kim | - |
dc.contributor.googleauthor | Sang-Hak Lee | - |
dc.contributor.googleauthor | Ung Kim | - |
dc.contributor.googleauthor | Shin-Jae Kim | - |
dc.contributor.googleauthor | Young Keun Ahn | - |
dc.contributor.googleauthor | Chang Hoon Lee | - |
dc.contributor.googleauthor | Jin Ho Shin | - |
dc.contributor.googleauthor | Mikyung Kim | - |
dc.contributor.googleauthor | Chang Gyu Park | - |
dc.identifier.doi | 10.1111/jch.13774 | - |
dc.contributor.localId | A02833 | - |
dc.relation.journalcode | J01320 | - |
dc.identifier.eissn | 1751-7176 | - |
dc.identifier.pmid | 32003938 | - |
dc.subject.keyword | amlodipine | - |
dc.subject.keyword | dyslipidemia | - |
dc.subject.keyword | hypertension | - |
dc.subject.keyword | rosuvastatin | - |
dc.subject.keyword | single-pill combination | - |
dc.contributor.alternativeName | Lee, Snag Hak | - |
dc.contributor.affiliatedAuthor | 이상학 | - |
dc.citation.volume | 22 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 261 | - |
dc.citation.endPage | 269 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL HYPERTENSION, Vol.22(2) : 261-269, 2020-02 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.